The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study

Hum Brain Mapp. 2016 Mar;37(3):1080-90. doi: 10.1002/hbm.23085. Epub 2016 Jan 29.

Abstract

Background: Low-dose ketamine has been found to have robust and rapid antidepressant effects. A hypoactive prefrontal cortex (PFC) and a hyperactive amygdala have been suggested to be associated with treatment-resistant depression (TRD). However, it is unclear whether the rapid antidepressant mechanisms of ketamine on TRD involve changes in glutamatergic neurotransmission in the PFC and the amygdala.

Methods: A group of 48 TRD patients were recruited and equally randomized into three groups (A: 0.5 kg/mg-ketamine; B: 0.2 kg/mg-ketamine; and C: normal saline [NS]). Standardized uptake values (SUV) of glucose metabolism measured by (18) F-FDG positron-emission-tomography before and immediately after a 40-min ketamine or NS infusion were used for subsequent region-of-interest (ROI) analyses (a priori regions: PFC and amygdala) and whole-brain voxel-wise analyses and were correlated with antidepressant responses, as defined by the Hamilton depression rating scale score. The (18) F-FDG signals were used as a proxy measure of glutamate neurotransmission.

Results: The ROI analysis indicated that Group A and Group B, but not Group C, had increases in the SUV of the PFC (group-by-time interaction: F = 7.373, P = 0.002), whereas decreases in the SUV of the amygdala were observed in all three groups (main effect of time, P < 0.001). The voxel-wise analysis further confirmed a significant group effect on the PFC (corrected for family-wise errors, P < 0.05; post hoc analysis: Group A<Group C, Group B<Group C). The SUV differences in the PFC predicted the antidepressant responses at 40 and 240 min post-treatment. The PFC changes did not differ between those with and without side effects.

Conclusion: Ketamine's rapid antidepressant effects involved the facilitation of glutamatergic neurotransmission in the PFC.

Keywords: glucose; ketamine; prefrontal cortex; treatment-resistant depression.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amygdala / diagnostic imaging
  • Amygdala / drug effects*
  • Antidepressive Agents / administration & dosage*
  • Antidepressive Agents / adverse effects
  • Depressive Disorder, Major / diagnostic imaging
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Treatment-Resistant / diagnostic imaging
  • Depressive Disorder, Treatment-Resistant / drug therapy*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / adverse effects
  • Female
  • Fluorodeoxyglucose F18
  • Glutamic Acid
  • Humans
  • Ketamine / administration & dosage*
  • Ketamine / adverse effects
  • Linear Models
  • Male
  • Middle Aged
  • Positron-Emission Tomography
  • Prefrontal Cortex / diagnostic imaging
  • Prefrontal Cortex / drug effects*
  • Psychiatric Status Rating Scales
  • Radiopharmaceuticals

Substances

  • Antidepressive Agents
  • Excitatory Amino Acid Antagonists
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Glutamic Acid
  • Ketamine

Associated data

  • JPRN/UMIN000016985